Shaker Barham, MD
Gastroenterology · Knoxville, TNNPI 1366825077
Payments from drug & device makers
Across 224 payments — averaging $49.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Olympus Corporation Of The Americas$2K
- AbbVie$1K
- Gilead$310
- Lilly USA, LLC$253
- Johnson & Johnson$237
- plus $2K from 32 others
What the payments were for
- Travel & lodging$5,35248%
- Food & beverage$5,68751%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $4,447 |
| Olympus Corporation Of The Americas | 21 | $2,255 |
| AbbVie | 67 | $1,498 |
| Gilead | 6 | $310 |
| Lilly USA, LLC | 7 | $253 |
| Johnson & Johnson | 11 | $237 |
| Madrigal Pharmaceuticals | 7 | $205 |
| Amgen | 6 | $196 |
| Olympus America Inc. | 3 | $166 |
| Medtronic | 5 | $156 |
| Lumendi LLC | 1 | $147 |
| Eisai Inc. | 1 | $112 |
| Bristol Myers Squibb | 6 | $103 |
| Alcresta Therapeutics, Inc. | 1 | $100 |
| Ardelyx, Inc. | 5 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $88 |
| Celltrion USA Inc. | 3 | $66 |
| Sanofi | 4 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Aimmune Therapeutics, Inc. | 2 | $50 |
| Intercept Pharmaceuticals, Inc. | 2 | $50 |
| Boehringer Ingelheim | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Merck | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| AstraZeneca | 1 | $28 |
| Pinnacle Biologics, Inc | 1 | $25 |
| Mauna Kea Technologies, Inc. | 1 | $24 |
| VBI Vaccine (delaware) Inc. | 1 | $24 |
| Novo Nordisk | 1 | $20 |
| Organon | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Capsovision, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Single Use Electrosurgical Knife KD-655$1,915
- DISPOSABLE DISTAL ATTACHMENT$1,915
- AXIOS$1,882
- GENERAL - THERAPIES$1,687
- Olympus$1,422
- SPYGLASS$296
- DiLumen EZ1, 103 cm$147
- DiLumen EZ1, 130 cm$147
- EXALT Model D$134
- OMVOH$122
- Vemlidy$113
- LENVIMA$112
- Creon$110
- Epclusa$109
How this compares
$11,145 in reported general payments places this provider in the 75th percentile of 336 gastroenterology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 32 | $257,159 |
| XifaxanRifaximin | 54 | $203,091 |
| CreonLipase/Protease/Amylase | 16 | $53,842 |
| LinzessLinaclotide | 28 | $32,539 |
| Dexlansoprazole DrDexlansoprazole | 43 | $13,365 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 41 | $6,664 |
| Budesonide DrBudesonide | 14 | $2,889 |
| Pantoprazole Sodium | 180 | $2,328 |
| Lactulose | 20 | $1,922 |
| CholestyramineCholestyramine (With Sugar) | 20 | $1,560 |
| Azathioprine | 14 | $1,509 |
| Sucralfate | 17 | $1,458 |
| Omeprazole | 96 | $1,406 |
| Famotidine | 98 | $1,087 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 14 | $847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Creon, Linzess | $1,498 | $343,54076 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $90 | $203,09154 claims |
| Braintree Laboratories, Inc.Sutab | $19 | $6,66441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Knoxville
- Raj NarayaniKnoxville$216K
- Carlos RollhauserKnoxville$144K
- Jason HuffmanKnoxville$105K
- William ErgenKnoxville$49K
- Meade EdmundsKnoxville$21K
- Thomas YoungKnoxville$20K
- Ziad YounesGermantown$15.6M
- Robert HerringNashville$3.2M
- Dawn Borromeo BeaulieuNashville$2.1M
- David SchwartzNashville$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.